SEARCH

SEARCH BY CITATION

References

  • 1
    Keino-Masu K,Masu M,Hinck L,Leonardo ED,Chan SS,Culotti JG,Tessier-Lavigne M. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996; 87: 17585.
  • 2
    Fearon ER,Cho KR,Nigro JM,Kern SE,Simons JW,Ruppert JM,Hamilton SR,Preisinger AC,Thomas G,Kinzler KW,Vogelstein B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 4956.
  • 3
    Fang DC,Jass JR,Wang DX. Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. J Clin Pathol 1998; 51: 5936.
  • 4
    Latil A,Chene L,Cochant-Priollet B,Mangin P,Fournier G,Berthon P,Cussenot O. Quantification of expression of netrins, slits and theirreceptors in human prostate tumors. Int J Cancer 2003; 103: 30615.
  • 5
    Enomoto T,Fujita M,Cheng C,Nakashima R,Ozaki M,Inoue M,Nomura T. Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 1995; 71: 4627.
  • 6
    Saegusa M,Machida D,Okayasu I. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression. Br J Cancer 2000; 82: 5718.
  • 7
    Thompson AM,Morris RG,Wallace M,Wyllie AH,Steel CM,Carter DC. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer 1993; 68: 648.
  • 8
    Murty VV,Li RG,Houldsworth J,Bronson DL,Reuter VE,Bosl GJ,Chaganti RS. Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene 1994; 9: 322731.
  • 9
    Hara A,Saegusa M,Mikami T,Okayasu I. Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 2001; 54: 8605.
  • 10
    Inokuchi K,Yamaguchi H,Hanawa H,Tanosaki S,Nakamura K,Tarusawa M,Miyake K,Shimada T,Dan K. Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res 2002; 8: 18828.
  • 11
    Huang Y,Boynton RF,Blount PL,Silverstein RJ,Yin J,Tong Y,McDaniel TK,Newkirk C,Resau JH,Sridhara R,Reid BJ,Meltzer SJ. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992; 52: 652530.
  • 12
    Dolan K,Garde J,Gosney J,Sissons M,Wright T,Kingsnorth AN,Walker SJ,Sutton R,Meltzer SJ,Field JK. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998; 78: 9507.
  • 13
    Jenkins GJ,Doak SH,Parry JM,D'Souza FR,Griffiths AP,Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002; 89: 82437.
  • 14
    Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nature 2004; 4: 97887.
  • 15
    Fazeli A,Dickinson SL,Hermiston ML,Tighe RV,Steen RG,Small CG,Stoeckli ET,Keino-Masu K,Masu M,Rayburn H,Simons J,Bronson RT, et al. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 1997; 386: 796804.
  • 16
    Klingelhutz AJ,Hedrick L,Cho KR,McDougall JK. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 1995; 10: 15816.
  • 17
    Mehlen P,Rabizadeh S,Snipas SJ,Assa-Munt N,Salvesen GS,Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998; 395: 8014.
  • 18
    Mehlen P,Bredesen DE. The dependence receptor hypothesis. Apoptosis 2004; 9: 3749.
  • 19
    Forcet C,Ye X,Granger L,Corset V,Shin H,Bredesen DE,Mehlen P. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci USA 2001; 98: 341621.
  • 20
    Wu TT,Watanabe T,Heitmiller R,Zahurak M,Forastiere AA,Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998; 153: 28794.
  • 21
    Raja S,Finkelstein SD,Baksh FK,Gooding WE,Swalsky PA,Godfrey TE,Buenaventura PO,Luketich JD. Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg 2001; 72: 11305.
  • 22
    Ogi K,Toyota M,Ohe-Toyota M,Tanaka N,Noguchi M,Sonoda T,Kohama G,Tokino T. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002; 8: 316471.
  • 23
    Carvalho AL,Chuang A,Jiang WW,Lee J,Begum S,Poeta L,Zhao M,Jeronimo C,Henrique R,Nayak CS,Park HL,Brait MR, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006; 66: 94017.
  • 24
    Miyamoto K,Fukutomi T,Akashi-Tanaka S,Hasegawa T,Asahara T,Sugimura T,Ushijima T. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005; 116: 40714.
  • 25
    Sato K,Tamura G,Tsuchiya T,Endoh Y,Usuba O,Kimura W,Motoyama T. Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br J Cancer 2001; 85: 199203.
  • 26
    Yamashita K,Upadhyay S,Osada M,Hoque MO,Xiao Y,Mori M,Sato F,Meltzer SJ,Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2: 4859.
  • 27
    Harden SV,Tokumaru Y,Westra WH,Goodman S,Ahrendt SA,Yang SC,Sidransky D. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003; 9: 13705.
  • 28
    Ishii T,Murakami J,Notohara K,Cullings HM,Sasamoto H,Kambara T,Shirakawa Y,Naomoto Y,Ouchida M,Shimizu K,Tanaka N,Jass JR, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007; 56: 1319.
  • 29
    Liu Z,Zhang L,Ding F,Li J,Guo M,Li W,Wang Y,Yu Z,Zhan Q,Wu M,Liu Z. 5-Aza-2′-deoxycytidine induces retinoic acid receptor-β(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett 2005; 230: 27183.
  • 30
    Kuroki T,Trapasso F,Yendamuri S,Matsuyama A,Alder H,Mori M,Croce CM. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 14415.
  • 31
    Xing EP,Nie Y,Wang L-D,Yang G-Y,Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999; 20: 7784.
  • 32
    Hibi K,Taguchi M,Nakayama H,Takase T,Kasai Y,Ito K,Akiyama S,Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 31358.
  • 33
    Kohno T,Sato T,Takakura S,Takei K,Inoue K,Nishioka M,Yokota J. Mutation and expression of the DCC gene in human lung cancer. Neoplasia 2000; 2: 3005.
  • 34
    Zhang J,Ding F,Wang X. [Expression and loss of heterozygosity of DCC gene in human lung cancer]. Zhonghua Yi Xue Za Zhi 1995; 75: 21113,254–5.